Ghasoub Harb, MD
Urology · Davenport, IANPI 1356344287
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Johnson & Johnson at 46.5% of the total. Reporting peaked in 2019 at $9,200 and has fallen 95.8% since, to $385 in 2025.
Across 119 payments — averaging $119.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$7K
- Bayer$3K
- Neotract Inc.$2K
- Accord Healthcare, Inc.$763
- Astellas Pharma US Inc$372
- Teleflex LLC$265
- plus $2K from 22 others
What the payments were for
- Consulting fees$7,18350%
- Speaking & faculty fees$7505%
- Travel & lodging$2,08215%
- Food & beverage$3,22223%
- Education$7555%
- Gifts$2392%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 16 | $6,610 |
| Bayer | 19 | $2,710 |
| Neotract Inc. | 25 | $1,913 |
| Accord Healthcare, Inc. | 2 | $763 |
| Astellas Pharma US Inc | 6 | $372 |
| Teleflex LLC | 4 | $265 |
| Pfizer | 10 | $246 |
| Tosoh Bioscience, Inc. | 1 | $239 |
| Dendreon Pharmaceuticals LLC | 12 | $216 |
| Pharmaand GmbH | 1 | $120 |
| Tolmar, Inc. | 1 | $120 |
| Stryker | 1 | $115 |
| Sumitomo Pharma America, Inc. | 1 | $108 |
| Coloplast | 1 | $73 |
| AbbVie | 4 | $69 |
| Myriad Genetic Laboratories, Inc. | 2 | $56 |
| Valencia Technologies Corporation | 2 | $41 |
| Isoray, Inc | 1 | $35 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Merck | 1 | $23 |
| Novartis | 1 | $18 |
| Dornier Medtech America, Inc | 1 | $18 |
| Progenics Pharmaceuticals, Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Amgen | 1 | $16 |
| Myovant Sciences Inc. | 1 | $15 |
| Janssen Scientific Affairs, LLC | 1 | $13 |
| Ambu Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$6,159
- Non-Covered$2,224
- UroLift$1,512
- CAMCEVI$750
- Rubraca$241
- PA, ST AIA-PACK$239
- UroLift System$132
- AKEEGA$128
- ELIGARD$120
- 1588 HD 3 CHIP CAMERA$115
- ORGOVYX$108
How this compares
$14,231 in reported general payments places this provider in the 85th percentile of 114 urology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 343 | $4,986,654 |
| XtandiEnzalutamide | 235 | $3,024,364 |
| NubeqaDarolutamide | 156 | $1,971,303 |
| OrgovyxRelugolix | 182 | $503,349 |
| LynparzaOlaparib | 24 | $220,579 |
| Abiraterone Acetate | 178 | $155,105 |
| MyrbetriqMirabegron | 51 | $43,296 |
| GemtesaVibegron | 15 | $10,386 |
| Dutasteride | 211 | $7,204 |
| Tamsulosin Hcl | 384 | $6,671 |
| Silodosin | 31 | $2,780 |
| Doxazosin Mesylate | 169 | $2,617 |
| Finasteride | 155 | $1,827 |
| Doxycycline Monohydrate | 75 | $1,504 |
| Bicalutamide | 51 | $1,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $6,610 | $4,986,654343 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $372 | $3,067,660286 claims |
| BayerNubeqa | $2,710 | $1,971,303156 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $108 | $513,735197 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $13 | $155,105178 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 114 urology providers in Iowa.
Other urology in Davenport
- David RohlfDavenport$3K
- Mark MillemanDavenport$2K
- Matthew BreamDavenport$1K
- Vignesh PackiamIowa City$112K
- Annah VollstedtIowa City$66K
- Bradley EricksonIowa City$65K
- Michael OdonnellIowa City$62K
- Kevin BirusinghDes Moines$59K
- Ryan DornbierClive$55K
- Alexandria HertzIowa City$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.